Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology

5 Jan 2023

Abstract excerpt

Patient-derived tumor xenograft (PDX)/organoid (PDO), driven by cancer stem cells (CSC), are considered the most predictive models for translational oncology. Large PDX collections reflective of patient populations have been created and used extensively to test various investigational therapies, including population-trials as surrogate subjects in vivo. PDOs are recognized as in vitro surrogates for patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Cancer Genomics and Diagnostics
Share to Chemical Reactions and Isotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36602988
DOI: 10.1371/journal.pone.0279821

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacologyPMID 36602988Read ↗

A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacologySemantic proximity Read ↗

Optimized large-scale longitudinal biorepository of gastroesophageal adenocarcinoma patient-derived organoids: High-fidelity models for personalized treatment to overcome resistanceSemantic proximity Read ↗

Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer modelsSemantic proximity Read ↗

Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugsSemantic proximity Read ↗

<em>Ex Vivo</em> Drug Testing of Patient-Derived Lung Organoids to Predict Treatment Responses for Personalized MedicineSemantic proximity Read ↗

A Self-Assembling Immune-Featured Osteosarcoma Patient/PDX Derived Organoid Model and Biobank for Personalized Immune TherapySemantic proximity Read ↗

XENTURION, a multidimensional resource of xenografts and tumoroids from metastatic colorectal cancer patients for population-level translational oncologySemantic proximity Read ↗

Patient-derived organoids across cancers reveal conserved tumor heterogeneity and actionable therapeutic vulnerabilities.Semantic proximity Read ↗

Patient-derived organoids in translational oncology and drug screeningSemantic proximity Read ↗

Long-term maintenance of patient-specific characteristics in tumoroids from six cancer indications in a common base culture media systemSemantic proximity Read ↗

Pancreatic adenocarcinoma human organoids share structural and genetic features with primary tumorsSemantic proximity Read ↗

Combining molecular characteristics and therapeutic analysis of PDOs predict clinical responses and guide PDAC personalized treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.